Bifidobacterium breve BB-C45 and application thereof in relieving symptoms of ulcerative colitis

By developing Bifidobacter brevis BB-C45 with good temperature and gastrointestinal fluid tolerance, the problem of easily inactivation of the bacteria during preservation and delivery in the prior art is solved, and the effect of effectively alleviating the symptoms of ulcerative colitis is achieved.

CN120158387APending Publication Date: 2025-06-17ZHONGCHUANG YIKE (SHANGHAI) BIOTECHNOLOGY CO LTD +1
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202411988960.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-31
Publication Date
2025-06-17

Smart Images

  • Figure CN120158387A_ABST
    Figure CN120158387A_ABST
Patent Text Reader

Abstract

The invention discloses bifidobacterium breve BB-C45 and application of the bifidobacterium breve BB-C45 in relieving symptoms of ulcerative colitis. The bifidobacterium breve BB-C45 is preserved in the China Center for Type Culture Collection on December 4, 2023, and the preservation number is CCTCC NO: M 20232445. A product prepared from the bifidobacterium breve BB-C45 disclosed by the invention has the beneficial effect of relieving symptoms of ulcerative colitis. Besides, the bifidobacterium breve BB-C45 has good temperature tolerance and gastrointestinal fluid tolerance, is convenient to store after commercial products are prepared, and can survive in intestines and stomach more easily, so that the purpose of relieving ulcerative colitis symptoms is achieved, and therefore, the bifidobacterium breve BB-C45 has a very good application prospect.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Bifidobacterium breve C11 and application thereof

    CN106038611A

  • Bifidobacterium breve and application thereof

    CN111996153A

  • Bifidobacterium capable of relieving colitis and application thereof

    CN113897302A

  • Bifidobacterium breve B2798 and application thereof in preparation of probiotic preparation

    CN116731891A

  • Probiotics capable of antagonizing intestinal enterobacteriaceae and relieving colitis

    CN118126894A